Dextera Surgical Inc

Dextera Surgical — Cardica — Shareholder Meeting (January 2016)

26 slides from Dextera Surgical's shareholder meeting presentation, Jan 29, 2016

  1. Slide 1: Annual Meeting Update

    Ce @ cardica. (NASDAQ: CRDC) Annual Meeting Update JANUARY 29, 2016

  2. Slide 2: Forward-Looking Statement

    FORWARD-LOOKING STATEMENT The following material contains forward-looking statements, including statements regarding Cardica’s future, business strategy, product development and plans and objectives of management for future operations. The words "may,” “continue,” “potential,” “estimate,” “intend,”

  3. Slide 3: Cardica Is...

    CARDICA IS... .. focused on commercializing our next-generation MicroCutter product line, which is designed to be a disruptive leader in the $2 billion surgical stapler market. Under new leadership, we believe we are positioned to achieve several milestones during calendar year 2016, including incre

  4. Slide 4: Investment Considerations

    INVESTMENT CONSIDERATIONS u Addressing a $2B market opportunity = Novel proprietary technology provides clinical and economic benefits to hospitals, surgeons and patients = Industry recognition as an innovative and disruptive participant in surgical staplers u Positioned to achieve several value cre

  5. Slide 5: Market Opportunity

    MARKET OPPOR $2B global market for minimally invasive surgical procedures ETHICON, ENDO-SURGERY, Ne *phnen ee nso @cardica

  6. Slide 6: Total U.S. Surgeries

    TOTAL U.S. SURGERIES o amoral es Colorectal 413k Estimated / 2,500,000 Procedures Pediatric 53k Annually Total Available U.S. Market > Ob/Gyn 400k General surgery (appendectomy and _} cholecystectomy) 1,075k Urologic 165k Parenchymal 82k Bariatric 155k Source: Quattro Consulting and Company estimate

  7. Slide 7: U.S. Endo Stapling Market

    U.S. ENDO STAPLING MARKET Staple Height U.S. ($MM) Mix Thin/Vascular $374 42% Medium $333 37% @ = Thick $187 21% Total $894 100% @ Vascular Firings represent a large market opportunity Source: IMS Data & Company Estimates 016 @cardica

  8. Slide 8: Competitors Not Meeting Market Needs

    COMPETITORS NOT MEETING MARKET NEEDS ay OTT A 3 N Too Big ® WY Limited \ Articulation * Not rhs Too ; Ergonomic 7 \ Complex es @cardica

  9. Slide 9: Size Matters for Staplers

    SIZE MATTERS FOR STAPLERS 5mm 8mm 12mm 15mm p> —_—_———- AF Grasper ° @ © O | e Camera —<— Clip Applier e ics Sealing Device e f< Current Staplers © Sn; == = @0ooo0o @0O00 O @ @ @

  10. Slide 10: MicroCutter Meets the Market's Needs

    MICROCUTTER MEETS THE MARKET’S NEEDS MicroCutter is the smallest articulating stapler available today and nearly 6x smaller in cross-sectional area. @cardica.

  11. Slide 11: MicroCutter: A Disruptive Stapler Innovation

    MICROCUTTER: A DISRUPTIVE STAPLER INNOVATION Brings innovation to minimally invasive surgery THE MOST ARTICULATION = At 802, it's almost double the articulation offered > Ld by existing stapl y existing staplers. = fm 0 5mm DIAMETER SHAFT IS INDUSTRY LEADING _S ‘= The most common existing staplers a

  12. Slide 12: Unique and Robust Intellectual Property

    UNIQUE AND ROBUST INTELLECTUAL PROPERTY system with staples us. 41 Issued 47 Pending ona strip ae deployment Patents Foreign 8 Issued —_35 Pending Expiration Staples are in the shape of __ Range AWE 9 ES \ a suture needle Staple is deployed by a wedge element (without a driver) making direct contact

  13. Slide 13: Key Drivers to Successful Staple Performance

    KEY DRIVERS TO SUCCESSFUL STAPLE PERFORMANCE = Control of the “Tissue Gap” during deployment a Uniform and reliable Staple Form Height - Paramount to providing tissue opposition and creating hemostasis! a Tissue thickness Internal staple form height If the tissue gap is controlled, the When the prop

  14. Slide 14: Optimization Plan Leading to Improved Performance

    OPTIMIZATION PLAN LEADING TO IMPROVED PERFORMANCE Stapler a A systematic characterization was conducted of all components in the stapler that impact performance and reliability. = Components/processes were modified to achieve a stable delivery platform, design validation was conducted to confirm per

  15. Slide 15: Staple Formed Height Results

    STAPLE FORMED HEIGHT RESULTS White Formed Height vs. Tissue Thickness Past, Present, Future White Formed Height ee Tissue Thickness

  16. Slide 16: White-Only Current Clinical Performance

    WHITE-ONLY CURRENT CLINICAL PERFORMANCE No Intervention | Bleeding with: Total Rate of Bleeding Intervention Deployments. with Intervention 158 <2% Current clinical performance @cardica

  17. Slide 17: Potential Clinical Impact

    POTENTIAL CLINICAL IMPACT LOW Enables procedure Pediatric surgery Polypectomies. ‘Trans-anal/NOTES Stapling penetration Facilitates procedure Thorai Microlobe HIGH Low HIGH Potential clinical impact of MicroCutter

  18. Slide 18: Strategic Segment Focus

    STRATEGIC SEGMENT FOCUS Parenchymal: 82K [$1,050/ procedure TAM: $86M] . t 0 i Heminepatectomy 1.000 aad These segments represent 280K procedures and a $380MM market in the U.S. alone. @cardica

  19. Slide 19: U.S. Commercialization Strategy, Approach and Metrics

    U.S. COMMERCIALIZATION STRATEGY, APPROACH AND METRICS = Tightly controlled direct sales effort focused on select KOLs = Focused on narrow and deep penetration = Show performance and deep penetration before investing in broader distribution = Initial phase for MC IIIc, followed by next-generation MC

  20. Slide 20: Building Market Awareness

    BUILDING MARKET AWARENESS m= Expanded agreement with Intuitive Surgical for robotic applications a MicroCutter highlighted in European thoracic surgery presentations at EACTS, WCS, Cambridge VATS Course mu In January 2016, MicroCutter featured as part of the Lung Surgery of the Future session at the

  21. Slide 21: What Are Thoracic Surgeons Saying

    WHAT ARE THORACIC SURGEONS SAY “I will probably be able to eliminate one of the robotic arms I use in a lobectomy with MicroCutter.” (Community based thoracic surgeon) (Highly experienced ‘obotic surgeon) “This will make it much easier for me to do uniportal.” (KOL VATS surgeon)

  22. Slide 22: Financial Update and Cap Table

    FINANCIAL UPDATE AND CAP TABLE At 9/30/15 = Product revenue ~$700k per quarter = Cash balance $22 million = Cash burn rate goal <$3.5 million quarterly Common stock outstanding 89,018,550 Preferred stock outstanding 191,474 Options and RSUs outstanding 9,390,648 = Average option price $0.69

  23. Slide 23: CY 2016 Milestones

    CY 2016 MILESTONES 2016 Qu Q2 Q3 a4 Receive FDA clearance for expanded indication > Gen IIIc limited launch === Demonstrate KOL adoption for VATS and pediatrics Complete Gen IV design and ——- first evaluation cases Launch Gen IV =» Oe = evaluation phase Supply chain optimization __ Establish product

  24. Slide 24: New Management Team: Proven Med-Tech Leaders

    NEW MANAGEMENT TEAM: PROVEN MED-TECH LEADERS Julian Nikolchev President, CEO & Director (Oct. 2015) 1 Founder, CEO & CTO, Pivot Medical 1 Founder, President & CEO, CardioMind 1 President & CEO Pro“Duct Health = Founder & CTO, Conceptus = Stanford, BS & MS; MIT, MS Tom Palermo Chief Operating Officer

  25. Slide 25: Summary

    SUMMARY Company is at an inflection point m= New management leaders with proven commercial track record = Improving performance, encouraging feedback and clinical adoption with target KOLs = Intuitive Surgical agreement adds support and credibility = Next-generation MicroCutter designed to expand pr

  26. Slide 26: cardica.

    @ cardica.

Cardica — Shareholder Meeting (January 2016) on 6ix